GH Research (GHRS) Competitors

GH Research (NASDAQ:GHRS) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Is GHRS or SGMO more profitable?

GH Research has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -257.87%. GH Research's return on equity of -19.81% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.81%	-19.10%
Sangamo Therapeutics	-257.87%	-264.16%	-107.24%

Does the MarketBeat Community prefer GHRS or SGMO?

Sangamo Therapeutics received 424 more outperform votes than GH Research when rated by MarketBeat users. However, 70.97% of users gave GH Research an outperform vote while only 62.55% of users gave Sangamo Therapeutics an outperform vote.

Company	Underperform	Outperform
GH Research	Outperform Votes 22 70.97%	Underperform Votes 9 29.03%
Sangamo Therapeutics	Outperform Votes 446 62.55%	Underperform Votes 267 37.45%

Which has more volatility & risk, GHRS or SGMO?

GH Research has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

Do institutionals & insiders have more ownership in GHRS or SGMO?

56.9% of GH Research shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 41.6% of GH Research shares are owned by company insiders. Comparatively, 2.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has preferable earnings & valuation, GHRS or SGMO?

GH Research has higher earnings, but lower revenue than Sangamo Therapeutics. GH Research is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$35.59M	-$0.79	-11.51
Sangamo Therapeutics	$176.23M	2.43	-$257.83M	-$0.75	-2.73

Do analysts prefer GHRS or SGMO?

GH Research currently has a consensus price target of $36.67, suggesting a potential upside of 303.37%. Sangamo Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 241.46%. Given GH Research's stronger consensus rating and higher probable upside, equities analysts clearly believe GH Research is more favorable than Sangamo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Sangamo Therapeutics	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Does the media refer more to GHRS or SGMO?

In the previous week, Sangamo Therapeutics had 8 more articles in the media than GH Research. MarketBeat recorded 20 mentions for Sangamo Therapeutics and 12 mentions for GH Research. Sangamo Therapeutics' average media sentiment score of 0.66 beat GH Research's score of 0.38 indicating that Sangamo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sangamo Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

GH Research beats Sangamo Therapeutics on 9 of the 17 factors compared between the two stocks.